Translational Analysis of Gait as a Primary Outcome Measure in Angelman Syndrome

$330,245 2020 FT2020-005

Translational Analysis of Gait as a Primary Outcome Measure in Angelman Syndrome

Dr. Duis used the ActiMyo device(s) in a clinical study to evaluate the tolerability and gait parameters in Angelman syndrome. This device was shown to be well tolerated and associated with various unique gait parameters when compared to neurotypical age-matched controls.

Principle Investigator

Jessica Duis, MD and Jill Silverman, PhD

For Researchers

For Pharma

For Families & Caregivers

For Donors & Investors

Translational Analysis of Gait as a Primary Outcome Measure in Angelman Syndrome

Translational Analysis of Gait as a Primary Outcome Measure in Angelman Syndrome

Principle Investigator